LONDON--(BUSINESS WIRE)--The primary sclerosing cholangitis treatment market is poised to grow by USD 37.50 million during 2020-2024, progressing at a CAGR of almost 4% during the forecast period. For ...
DelveInsight's,“ Primary Biliary Cholangitis Pipeline Insight 2025 ” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Primary Biliary Cholangitis pipeline landscape ...
Data expected H2 2026Rare liver disease with no approved treatment, typically concurrent with Inflammatory Bowel Disease (IBD)Second YAQ001 ...
Three-year data from ongoing open-label study supported safety and effectiveness of seladelpar in patients with primary biliary cholangitis.
DelveInsight's “Primary Sclerosing Cholangitis Pipeline Insights 2025” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Primary Sclerosing Cholangitis pipeline ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new long-term data reinforcing the safety and efficacy profile of ...
The survey of European hepatologists demonstrates the lack of clarity in guidelines. A new survey of European health care centers with expertise in managing primary sclerosing cholangitis (PSC) ...
In medicine, treatment goals set by physicians might differ from patient priorities. Although normalisation of laboratory parameters is a target supported by outcomes data, patient perspectives ...
Ahmad Anouti, MD, a pediatric resident at UT Southwestern Medical Center, spoke with Healio about treatments in the primary biliary cholangitis pipeline.He noted one therapy making strides in the ...
New safety and efficacy data for primary biliary cholangitis (PBC) treatment Livdelzi (seladelpar) was presented today at The Liver Meeting, hosted by the American Association for the Study of Liver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback